Company intelligence / Profile preview

Emmes

Rockville, Maryland, United Statestheemmesgroup.com ↗

Ownership: Private
Employees: ~1525
Development stage: Other

Overview

Emmes has supported over 2,150 Phase I–IV clinical trials across 90+ countries. It has played key roles in landmark studies such as AREDS/AREDS2 for ophthalmology and major public health initiatives with the NIH. Its expertise spans vaccines/infectious disease, rare disease research including cell/gene therapies, neuroscience, oncology/hematology, maternal/child health. It leverages advanced digital platforms and AI to accelerate trial execution with high quality outcomes

Therapeutic areas: Rare DiseasesNeurologyInfectious DiseasesOphthalmologyHematologyOncologyWomen's Health
Modalities: Cell therapyGene therapy
Industry: Contract Research Organization

Partnerships

National Institutes of Health (NIH)Food and Drug Administration (FDA)Department of Defense (DOD)Gates FoundationPATHIAVI15 of the top 25 global biopharma companies

Beyond the preview

Go deeper on Emmes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emmes.